Kurt Graves, former Intarcia Therapeutics CEO

Once val­ued at more than $5B, Intar­cia Ther­a­peu­tics sees all of its ex­ecs de­part and its fi­nal shot at FDA de­nied

The last mem­bers of its ex­ec­u­tive team have moved on, the phone num­ber at its Boston-based HQ has been shut off, and as of ear­li­er this month, the FDA has de­nied Intar­cia Ther­a­peu­tics’ fi­nal re­quest for a hear­ing to re-re­view the com­pa­ny’s twice-re­ject­ed type 2 di­a­betes drug can­di­date and pro­pri­etary de­liv­ery sys­tem.

The let­ter from the FDA ear­li­er this month caps a near­ly five-year saga from when the FDA first re­ject­ed Intar­cia’s twice-year­ly type 2 di­a­betes drug, known as IT­CA 650, af­ter call­ing on the com­pa­ny to ad­dress ex­ten­sive clin­i­cal de­fi­cien­cies, and de­vice and prod­uct qual­i­ty-re­lat­ed is­sues.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.